Otezla FDA Approval History
Last updated by Judith Stewart, BPharm on July 20, 2019.
FDA Approved: Yes (First approved March 21, 2014)
Brand name: Otezla
Generic name: apremilast
Dosage form: Tablets
Company: Celgene Corporation
Treatment for: Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease
Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.
Development timeline for Otezla
| Date | Article |
|---|---|
| Sep 8, 2022 | Amgen Announces Positive New Data for Otezla |
| Dec 20, 2021 | Approval FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level |
| Jul 19, 2019 | Approval FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease |
| Sep 23, 2014 | Approval FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis |
| Mar 21, 2014 | Approval FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
